We want to save as many animal lives as possible.
In order to fulfill such goal, we apply regenerative medicine that is now being put to practical use in humans to animals.
For this purpose, we utilize our proprietary animal iPS cell technology that enables us to deliver high-quality regenerative medicine unlike relying on living animal donors. Hence, we hope iPS cells to be the heart of animal regenerative medicine.
We started development of iPS cells-derived regenerative medicine products, firstly with dogs.
And, safety is the first and foremost important thing for bringing regenerative medicine to animals.
We also value the security of veterinarians and people whose partner animals are treated.
We grow this technology in the same way as we hold the passion to nurture our dogs, cats, and other precious partner animals, and aim our goal that is to create a society in which both people and animals can live happily.
Originating from unique canine iPS cells The technology to establish iPS cell lines in dogs and other animals was established by a joint research project between Nihon University and Keio University.
A unique set of reprogramming factors is transfected into cells without the use of viruses, resulting in canine iPS cells that can maintain their pluripotency for a long period of time and are suitable for clinical applications. iPS cells can be differentiated into various types of cells and can be used to make a variety of regenerative medical products. Starting with dogs, Vetanic will induce the differentiation of canine mesenchymal stem cells (MSCs) from canine iPS cells, and aiming for the approval from the Ministry of Agriculture, Forestry and Fisheries as a qualified pharmaceutical product.
Fundamental technology
So called "Clinical grade" canine iPS cells
was produced by resolving the technical issues to date.
Core product
Inducing canine mesenchymal stem cells (MSCs) from canine iPS cells into a cell therapy product compliant with the Pharmaceuticals and medical devices Law.
Implementation of accessibleIn order to spread the animal regenerative medicine, we believe that this therapy should be an easy-to-use treatment option for many families, and it should be performed without placing a burden on the donor.
Since iPS cells can be cultured in large quantities, once they are produced, donor-dependent free regenerative medicine becomes possible. Moreover, the use of iPS cells will enable the development of a variety of regenerative medical products. We want to implement accessible and sustainable regenerative medicine by utilizing iPS cells.
2024.04.10ARTICLE
The article introducing Vetanic has been made available at Nikkei Biotechnology & Business Online on the 5th April 2024.
Please refer the online article from below URL link. (available to the subscription members only)
Nikkei Biotechnology & Business, 5th April 2024 特集連動◎多様化と高度化が進む動物薬 「Vetanic、イヌ・ネコのiPS細胞作製技術で複数疾患に対する再生医療等製品を開発」
